Send us a text

Marc Elia is the Founder of M28 Capital ( https://www.m28capital.com/ ), a healthcare sector investment fund, as well as Chairman of the Board of Invivyd ( https://www.invivyd.com/ ), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, by deploying a proprietary integrated technology platform, to create best in class monoclonal antibodies.

In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates.

Marc has a passion for investing in and developing innovative healthcare solutions, and dedicated much of his career to make a meaningful difference in human health, and advocate for the development of therapies that address unmet medical needs.

Prior to M28, from January 2012 to September 2019, Marc served as a partner at Bridger Capital, an investment fund and has served on the Board of Directors of numerous companies.

Prior to his time in the healthcare investment space, Marc served in Strategy and Corporate Development roles at Chiron Corporation, in Business Development at Protein Sciences Corporation, as well as in consulting at L.E.K. Consulting.

Marc holds a B.A. in economics from Carleton College.

#MarcElia #M28Capital #Invivyd #Biopharmaceuticals #InfectiousDiseases #SARSCoV2 #MonoclonalAntibodies #Immunocompromised #RareViralEpitopes #Pemivibart #PreExposureProphylaxis #Covid19 #EmergencyUseAuthorization #EUA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show